Investor deep dive
Analysts eye more licensing deals for Avacta’s Affimer technology in 2019
Avacta Group - Exciting partnership with Bach BioSciences
Avacta Group Plc (LON:AVACT) has recently finalised a co-development partnership with Boston-based Bach BioSciences, to exploit the potential of the Affimer platform for the development of a novel class of drug conjugates.
Despite the favourable reaction to the announcement of the Bach Biosciences agreement (stock up 35%), Avacta’s market capitalisation is still much lower than biotech peers that have unique protein-based platforms and drug candidates in the clinical stage, where Avacta is on track to be by 2020.
Quick facts: Avacta Group PLC
Market Cap: £26.02 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Avacta Group PLC named herein, including the promotion by the Company of Avacta Group PLC in any Content on the Site, the Company receives from...FOR OUR FULL DISCLAIMER CLICK HERE
LEGAL NOTICE – IMPORTANT – PLEASE READ:
Proactive Research is a trading name of Proactive Investors Limited which is regulated and authorised by the Financial Conduct Authority (FCA) under firm registration...FOR OUR FULL DISCLAIMER CLICK HERE